Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | PDXK | O00764 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29733341 | 0.98 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL191715 | 0.98 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL28098773 | 0.96 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3442719 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL16418384 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3804399 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.81 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.81 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL21657969 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.81 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | claimed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| WO-2023091990-A1 | COMPOSITIONS AND METHODS TARGETING GABA SIGNALING PATHWAY FOR SOLID TUMOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2023-05-25 | — | — | WO | claimed |
| US-20210206820-A1 | TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR | PURDUE RESEARCH FOUNDATION | 2021-07-08 | — | — | US | claimed |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2020-08-20 | — | — | US | claimed |
| EP-3668506-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BioScience (CH) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034768-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | AC BIOSCIENCE (CH) | 2019-02-21 | — | — | WO | claimed |
| US-6025472-A | PEPTIDE ALDEHYDES WHICH ARE POTENT INHIBITORS OF FACTOR XA, USEFUL AS THERAPEUTIC AGENTS FOR DISEASE STATES IN MAMMALS CHARACTERIZED BY ABNORMAL THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 2000-02-15 | — | — | US | claimed |
| US-5696231-A | ANTICOAGULANTS; CARDIOVASCULAR DISORDERS | CORVAS INTERNATIONAL, INC. (US) | 1997-12-09 | — | — | US | claimed |
| EP-0801654-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES AS INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1997-10-22 | — | — | EP | claimed |
| WO-1996019493-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES AS INHIBITORS OF FACTOR Xa | CORVAS INTERNATIONAL, INC. (US) | 1996-06-27 | — | — | WO | claimed |
| EP-4735008-A1 | IBOGAINE TREATMENT | Ambio Life Sciences Inc. (CA) | 2026-05-06 | — | — | EP | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| WO-2025000092-A1 | IBOGAINE TREATMENT | AMBIO LIFE SCIENCES INC. (CA) | 2025-01-02 | — | — | WO | disclosed |
| WO-1984003441-A1 | 2-ACYLIMIDAZOLE COMPOUNDS, THEIR SYNTHESIS AND USE AS IMMUNOSUPPRESIVE MEDICINAL AGENTS | COCA COLA CO (US) | 1984-09-13 | — | — | WO | disclosed |
| US-4212976-A | ANTIARTHRITIC AGENTS | MERCK & CO., INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4057637-A | RHEUMATOID ARTHRITIS | MERCK & CO., INC. (US) | 1977-11-08 | — | — | US | disclosed |
| US-3971797-A | ANTIARTHRITIC | MERCK & CO., INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | KDM4E 4515/4885ALDH1A1 3919/4885HPGD 1656/4885 |
| US-20200261420-A1 | ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY | SPHK1, S1PR1, S1PR2 | KDM4E 1799/4885ALDH1A1 2286/4885HPGD 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.